Mereo Biopharma Group Stock Analysis

MREO Stock  USD 2.93  0.06  2.09%   
Mereo BioPharma Group is undervalued with Real Value of 3.92 and Target Price of 7.22. The main objective of Mereo BioPharma stock analysis is to determine its intrinsic value, which is an estimate of what Mereo BioPharma Group is worth, separate from its market price. There are two main types of Mereo BioPharma's stock analysis: fundamental analysis and technical analysis.
The Mereo BioPharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Mereo BioPharma is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Mereo Stock trading window is adjusted to America/New York timezone.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

Mereo Stock Analysis Notes

About 66.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.25. Mereo BioPharma Group had not issued any dividends in recent years. Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. Mereo Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 49 people. To find out more about Mereo BioPharma Group contact Denise ScotsKnight at 44 33 3023 7300 or learn more at https://www.mereobiopharma.com.

Mereo BioPharma Group Investment Alerts

Mereo BioPharma generated a negative expected return over the last 90 days
Mereo BioPharma has high historical volatility and very poor performance
The company reported the previous year's revenue of 10 M. Net Loss for the year was (29.47 M) with profit before overhead, payroll, taxes, and interest of 936 K.
Mereo BioPharma Group currently holds about 94.3 M in cash with (21.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81.
Mereo BioPharma has a frail financial position based on the latest SEC disclosures
Roughly 66.0% of the company shares are owned by institutional investors

Mereo BioPharma Group Upcoming and Recent Events

Earnings reports are used by Mereo BioPharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
26th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Mereo Largest EPS Surprises

Earnings surprises can significantly impact Mereo BioPharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-09-05
2024-06-30-0.01-0.0862-0.0762762 
2020-06-15
2020-03-31-0.26-3.277-3.0171160 
View All Earnings Estimates

Mereo BioPharma Environmental, Social, and Governance (ESG) Scores

Mereo BioPharma's ESG score is a quantitative measure that evaluates Mereo BioPharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Mereo BioPharma's operations that may have significant financial implications and affect Mereo BioPharma's stock price as well as guide investors towards more socially responsible investments.

Mereo BioPharma Thematic Classifications

In addition to having Mereo BioPharma stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Mereo Stock Institutional Investors

Shares
Morgan Stanley - Brokerage Accounts2024-09-30
2.3 M
Goldman Sachs Group Inc2024-09-30
M
Renaissance Technologies Corp2024-09-30
1.3 M
Longwood Capital Partners Llc2024-09-30
1.3 M
Marshall Wace Asset Management Ltd2024-09-30
M
Integral Health Asset Management, Llc2024-09-30
1000 K
Blue Owl Capital Holdings Lp2024-09-30
847.8 K
Soleus Capital Management, L.p.2024-09-30
847 K
Neos Investment Management, Llc2024-09-30
835.2 K
Rubric Capital Management Lp2024-09-30
15.3 M
Hhg Plc2024-09-30
12.3 M
Note, although Mereo BioPharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Mereo Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 630.8 M.

Mereo Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.52)(0.54)
Return On Capital Employed(0.45)(0.47)
Return On Assets(0.51)(0.54)
Return On Equity(0.52)(0.50)

Management Efficiency

Mereo BioPharma Group has return on total asset (ROA) of (0.2386) % which means that it has lost $0.2386 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4847) %, meaning that it created substantial loss on money invested by shareholders. Mereo BioPharma's management efficiency ratios could be used to measure how well Mereo BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of January 2025, Return On Tangible Assets is likely to drop to -0.54. In addition to that, Return On Capital Employed is likely to drop to -0.47. At this time, Mereo BioPharma's Total Assets are very stable compared to the past year. As of the 30th of January 2025, Net Tangible Assets is likely to grow to about 45.6 M, while Non Current Assets Total are likely to drop about 2.3 M.
Last ReportedProjected for Next Year
Book Value Per Share 0.09  0.08 
Tangible Book Value Per Share 0.09  0.08 
Enterprise Value Over EBITDA(64.96)(68.21)
Price Book Value Ratio 27.13  28.49 
Enterprise Value Multiple(64.96)(68.21)
Price Fair Value 27.13  28.49 
Enterprise Value1.3 B1.4 B
Mereo BioPharma Group benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Operating Margin
(37.90)
Beta
0.97
Return On Assets
(0.24)
Return On Equity
(0.48)

Technical Drivers

As of the 30th of January, Mereo BioPharma secures the Risk Adjusted Performance of (0.1), standard deviation of 4.04, and Mean Deviation of 2.9. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mereo BioPharma Group, as well as the relationship between them.

Mereo BioPharma Group Price Movement Analysis

Execute Study
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Mereo BioPharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Mereo BioPharma Group. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Mereo BioPharma Group Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mereo BioPharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mereo BioPharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mereo BioPharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Scots-knight Denise few days ago
Acquisition by Scots-knight Denise of 825000 shares of Mereo BioPharma at 2.91 subject to Rule 16b-3
 
Scots-knight Denise over three weeks ago
Disposition of 92273 shares by Scots-knight Denise of Mereo BioPharma at 3.3932 subject to Rule 16b-3
 
Hughes-wilson Alexandra over two months ago
Acquisition by Hughes-wilson Alexandra of 93333 shares of Mereo BioPharma at 1.4 subject to Rule 16b-3
 
Fox Christine Ann over three months ago
Acquisition by Fox Christine Ann of 245000 shares of Mereo BioPharma at 3.36 subject to Rule 16b-3
 
Hughes-wilson Alexandra over three months ago
Disposition of 84008 shares by Hughes-wilson Alexandra of Mereo BioPharma at 4.221 subject to Rule 16b-3
 
Hughes-wilson Alexandra over three months ago
Disposition of 40029 shares by Hughes-wilson Alexandra of Mereo BioPharma at 4.4727 subject to Rule 16b-3
 
Hughes-wilson Alexandra over three months ago
Disposition of 75000 shares by Hughes-wilson Alexandra of Mereo BioPharma at 1.01 subject to Rule 16b-3
 
Hughes-wilson Alexandra over three months ago
Acquisition by Hughes-wilson Alexandra of 60000 shares of Mereo BioPharma subject to Rule 16b-3
 
Pakianathan Deepika over three months ago
Disposition of 55000 shares by Pakianathan Deepika of Mereo BioPharma at 0.94 subject to Rule 16b-3
 
Hughes-wilson Alexandra over six months ago
Disposition of 22968 shares by Hughes-wilson Alexandra of Mereo BioPharma at 3.3932 subject to Rule 16b-3
 
Hughes-wilson Alexandra over six months ago
Disposition of 10134 shares by Hughes-wilson Alexandra of Mereo BioPharma at 3.69 subject to Rule 16b-3
 
Yoskowitz Marc J over six months ago
Disposition of 9167 shares by Yoskowitz Marc J of Mereo BioPharma at 0.79 subject to Rule 16b-3

Mereo BioPharma Outstanding Bonds

Mereo BioPharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mereo BioPharma Group uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mereo bonds can be classified according to their maturity, which is the date when Mereo BioPharma Group has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Mereo BioPharma Predictive Daily Indicators

Mereo BioPharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Mereo BioPharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Mereo BioPharma Corporate Filings

F4
28th of January 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
23rd of January 2025
Other Reports
ViewVerify
8K
13th of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
6th of December 2024
Other Reports
ViewVerify
4th of December 2024
Other Reports
ViewVerify
25th of November 2024
Other Reports
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
10Q
12th of November 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify

Mereo BioPharma Forecast Models

Mereo BioPharma's time-series forecasting models are one of many Mereo BioPharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Mereo BioPharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Mereo Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Mereo BioPharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Mereo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Mereo BioPharma. By using and applying Mereo Stock analysis, traders can create a robust methodology for identifying Mereo entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(3.45)(3.62)
Operating Profit Margin(3.27)(3.10)
Net Loss(3.39)(3.56)
Gross Profit Margin 0.85  0.81 

Current Mereo Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Mereo analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Mereo analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
7.22Strong Buy7Odds
Mereo BioPharma Group current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Mereo analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Mereo stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Mereo BioPharma Group, talking to its executives and customers, or listening to Mereo conference calls.
Mereo Analyst Advice Details

Mereo Stock Analysis Indicators

Mereo BioPharma Group stock analysis indicators help investors evaluate how Mereo BioPharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Mereo BioPharma shares will generate the highest return on investment. By understating and applying Mereo BioPharma stock analysis, traders can identify Mereo BioPharma position entry and exit signals to maximize returns.
Begin Period Cash Flow68.2 M
Long Term Debt4.4 M
Common Stock Shares Outstanding659.5 M
Total Stockholder Equity50.5 M
Tax Provision-532 K
Property Plant And Equipment Net1.6 M
Cash And Short Term Investments57.4 M
Cash57.4 M
Accounts Payable2.3 M
Net Debt-51.5 M
50 Day M A4.289
Total Current Liabilities9.5 M
Other Operating Expenses38.4 M
Non Current Assets Total2.7 M
Stock Based Compensation4.9 M
When determining whether Mereo BioPharma Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mereo BioPharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mereo Biopharma Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mereo Biopharma Group Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.25)
Revenue Per Share
0.007
Return On Assets
(0.24)
Return On Equity
(0.48)
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.